• 6 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b...
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381-390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:1660
    Download:102
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains...
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313-342
    DOI: https://doi.org/10.37349/etat.2020.00019
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:861
    Download:29
    Open Access
    Case Report
    Pseudoprogression in lung cancer: a case report
    Immunotherapy dramatically changed the management of several malignancies including non-small cell lung cancer (NSCLC). Since immune checkpoint inhibitors have a different mechanism of action from c...
    Giulia Meoni ... Angela Stefania Ribecco
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372-380
    DOI: https://doi.org/10.37349/etat.2020.00022
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:895
    Download:19
    Times Cited: 0
    Open Access
    Original Article
    Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
    Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamox...
    Milene Volpato ... Valerie Speirs
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:355-371
    DOI: https://doi.org/10.37349/etat.2020.00021
    View:1336
    Download:26
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” ...
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273-312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:7917
    Download:1109
    Open Access
    Review
    Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
    Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small ...
    Giovanni Vicidomini ... Mario Santini
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:343-354
    DOI: https://doi.org/10.37349/etat.2020.00020
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:660
    Download:16
    Times Cited: 0